Cancer Genetics to Report Second Quarter 2018 Financial Results on August 14, 2018
August 07 2018 - 4:05PM
Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling
precision medicine for oncology through molecular markers and
diagnostics, today announced that it will release its financial
results for the second quarter ended June 30, 2018 on Tuesday,
August 14, 2018 during pre-market hours. The Company will hold a
conference call at 8:30 a.m. Eastern on Tuesday, August 14, 2018 to
discuss the financial results and provide an update on its
strategic direction and key organizational improvements being made
by the Company.
CONFERENCE CALL & WEBCAST |
Tuesday,
August 14, 2018, 8:30 a.m. Eastern Time |
Domestic: |
800-289-0438 |
International: |
323-794-2423 |
Conference ID: |
1766530 |
Webcast: |
http://public.viavid.com/index.php?id=130945 |
|
|
Replay –
Available through August 28, 2018 |
Domestic: |
844-512-2921 |
International: |
412-317-6671 |
Conference
ID: |
1766530 |
|
|
ABOUT CANCER GENETICS
Cancer Genetics, Inc. is a leader in enabling precision medicine
in oncology from bench to bedside through the use of oncology
biomarkers and molecular testing. CGI is developing a global
footprint with locations in the US, Australia and China. We have
established strong clinical research collaborations with major
cancer centers such as Memorial Sloan Kettering, The Cleveland
Clinic, Mayo Clinic, Keck School of Medicine at USC and the
National Cancer Institute.
The Company offers a comprehensive range of laboratory services
that provide critical genomic and biomarker information. Its
state-of-the-art reference labs are CLIA-certified and
CAP-accredited in the US and have licensure from several states
including New York State.
For more information, please visit or follow CGI
at:
Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward Looking Statements:
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements pertaining to Cancer Genetics
Inc.’s expectations regarding future financial and/or
operating results and potential for our tests and services, and
future revenues or growth in this press release constitute
forward-looking statements.
Any statements that are not historical fact
(including, but not limited to, statements that contain words such
as “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products, risks
of cancellation of customer contracts or discontinuance of trials,
risks that anticipated benefits from acquisitions will not be
realized, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
maintenance of intellectual property rights and other risks
discussed in the Cancer Genetics, Inc. Form 10-K for the year ended
December 31, 2017 along with other filings with the Securities and
Exchange Commission. These forward-looking statements speak only as
of the date hereof. Cancer Genetics, Inc. disclaims any obligation
to update these forward-looking statements.
INVESTOR CONTACTS:
Lee Roth The Ruth GroupTel: 646-536-7012 Email:
lroth@theruthgroup.com
Media:Kirsten ThomasThe Ruth GroupTel:
508-280-6592Email: kthomas@theruthgroup.com
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2023 to Jul 2024